ARTRYA®
Coronary Artery Disease.
We see you.

QUARTERLY ACTIVITIES & CASHFLOW REPORT
QUARTER ENDED 31 MARCH 2026

Investor Conference Call at 12.30pm AEST (10.30am AWST) on 1 May 2026 – including Tanner Health executives

PERTH, Australia, 30 April 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to release its Appendix 4C – Quarterly Cashflow Report and Activities Update for the quarter ended 31 March 2026 (the **Quarter**). All financial results are in Australian dollars and are unaudited.

Highlights

- **Commercial roll-out progressing with Salix® platform fully integrated across five Tanner Health hospitals and growing number of Salix® coronary plaque assessments building early revenue**
- **Salix® clinical integration and onboarding preparation of Northeast Georgia Health and Cone Health progressed with go-live expected beginning of FY27**
- **Salix® Coronary Flow module completed with high degree of accuracy and commercial features - final stage of clinical data validation of module is underway ahead of FDA 510(k) submission**
- **SAPPHIRE Study contracting and ethics approvals submissions underway at all six major U.S. hospital systems - ahead of planned Principal Investigator kick off meeting at the annual SCCT meeting in July 2026**
- **Strengthened Board and U.S. leadership including appointment of Dr. Jeffrey Le Benger as a director**
- **Artrya included in S&P/ASX All Ordinaries Index**
- **Pro forma cash position of $76.6M at 31 March 2026**

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"This Quarter we focused on building a solid commercial platform and early launch experience for our three U.S. foundational customers, as each will act as important reference sites for other potential customers we are currently engaging. I am very pleased to report that Tanner Health has fully integrated both the Salix® platform and Salix® Coronary Plaque module across all of their hospitals, demonstrating their confidence in Salix® and its clinical and operational benefits. We are also on track to have both Northeast Georgia Health System and Cone Health live and operational by the end of the June quarter, setting us up well as we move into the 2027 financial year.

A key priority for 2026 remains the submission and clearance of the Salix® Coronary Flow module and this is now in its final stages ahead of FDA submission, with the module calibrated and 'locked down' during the Quarter. Pleasingly, the accuracy of the module is highly encouraging and reinforces our confidence in its clinical utility and commercial potential. We are undertaking clinical data validation to support a robust, high-quality 510(k) package.

Looking forward, we have also enhanced our U.S. commercial capability with both Board and Leadership appointments. In parallel, our SAPPHIRE Study is moving well through the customary contracting and ethics processes and I look forward to the kick off meeting for the Study, targeted for June this year."

Commercial rollout progressing across three U.S. foundation customers

In the first quarter of 2026, Artrya continued to build a strong U.S. commercial foundation across all three current customers: Tanner Health, Northeast Georgia Health System (**NGHS**), and Cone Health.

Artrya's first U.S. customer, Tanner Health, has now fully integrated the Salix® Coronary Anatomy platform and Salix® Coronary Plaque module across all five hospitals. Salix® is live in clinical practice and is being used routinely by their clinicians. Reimbursement and back-office processes are in the final stages of completion across Tanner Health's payor network, supporting scan-based revenue generation and broader adoption of the Salix® Plaque module.

Reflecting the Salix® Coronary Anatomy's ease of use and clinical utility, Tanner Health's monthly scan volumes have increased consistently throughout the Quarter, driven by regular use of Salix® in the outpatient setting. The trend of increasing customer scan volumes and the associated fee-per-scan revenues is key for long term shareholder value.

As part of the relationship with Tanner Health, three of their senior executives are in Australia in April to meet with Artrya to build on the Salix® collaboration, meet with Artrya shareholders, and also identify new leading healthcare technologies for their business.

At NGHS, integration of Salix® Coronary Anatomy remains aligned with a concurrent PACS upgrade across their network, which will streamline image routing and reporting workflows. Significant preparatory work has been completed by Artrya, with deployment scheduled to commence in May and transition by NGHS into clinical use expected in the near term.

Cone Health also advanced its implementation preparation, with ongoing IT configuration and infrastructure setup. Artrya's Customer Success team continues to support clinical and technical onboarding within Cone Health's cardiology and IT service lines.

In the coming quarter, Artrya's commercial focus will be on expanding revenue at Tanner Health, its initial reference customer, by increasing weekly volumes of Salix® Plaque assessments. In parallel, the operations team will prioritise completion of integrations at NGHS and Cone Health, with the objective of all three customers being live and generating Salix® Coronary Anatomy and Plaque revenues from the start of the 2027 financial year.

SAPPHIRE Study preparing to commence with contracting and ethics processes underway

During this Quarter, Artrya secured the final two high-volume cardiology groups for the upcoming U.S. multi-centre SAPPHIRE Study, with the inclusion of Dignity Health Arizona and HCA Midwest Health. Both health systems bring extensive cardiovascular expertise, large-scale imaging volumes and experienced clinical leadership. The SAPPHIRE Study now has the six participants intended, with Mass General Brigham, Piedmont Health, Ascension and Huntsville Hospital Heart Centre.

The SAPPHIRE Study is a retrospective, real-world study looking to evaluate the prognostic and clinical utility of Salix® Plaque Analysis and Artrya's proprietary Plaque Dispersion Score to more accurately identify patients with elevated risk of cardiovascular events. Another major component is SAPPHIRE-WIN, a dedicated female cohort designed to address the well-recognised global challenge of diagnosing coronary artery disease in women, who are frequently asymptomatic and under-identified by conventional risk models.

Across all six hospital systems, protocol development and ethics submissions are progressing, with Salix® demonstrations commencing as part of early commercialisation activities. Each site is expected to contribute multiple imaging locations, supporting broad data capture and operational diversity. The six principal investigators are scheduled to convene for a formal SAPPHIRE study kick-off meeting at the Society of Cardiovascular Computed Tomography (**SCCT**) Annual Scientific Meeting 2026 in San Diego in mid-July 2026.

Strengthening U.S. leadership

This Quarter, Artrya continued to strengthen its governance and U.S. commercialisation capability, including the appointment of an experienced General Manager, U.S. Operations. This role is responsible for building and scaling the operational infrastructure required to support adoption of the Salix® platform across the U.S. market, encompassing, customer management, integration, support and customer success.

Additionally, Dr Jeffrey Le Benger was appointed as Artrya's second U.S.-based Director, bringing deep insight into commercial adoption, care-model transformation and deploying technology at scale across major health systems. During his tenure at Summit Health, Dr Le Benger grew the business into a leading multi-discipline healthcare provider, which was firstly acquired for US$8.9B in 2022 by the Walgreens Boots Alliance, followed by a subsequent US$10.0B acquisition in 2025 by private equity firm Sycamore Partners.

Salix® Coronary Flow module nearing FDA submission

The preparation for FDA submission of the Salix® Coronary Flow (**SCF**) module is in its final stages, with calibration, refinement and verification activities well advanced following the Q-Submission meeting with the U.S. Food and Drug Administration (**FDA**) in October 2025. The final version of the SCF module has been calibrated and 'locked down' and demonstrates strong accuracy in performance, providing confidence in its clinical utility and reinforcing its significant commercial potential upon clearance.

Artrya is completing its clinical study with the SCF module which is designed to generate the technical data to validate the module. This data will be included in the documentation for a comprehensive and high-quality 510(k) submission, with all workstreams aligned toward submission to the FDA in the near term. This remains a key priority, with Artrya focused on ensuring the submission reflects the same level of rigour, quality and regulatory compliance achieved with the Salix® Coronary Plaque module.

In parallel, Artrya's Customer Success team is advancing commercial readiness initiatives to support a smooth post-clearance launch, with the Salix® Coronary Flow module targeted for commercial rollout in the second half of 2026. While the module is integrated within the existing Salix® platform, additional work is underway to finalise training materials and reimbursement pathways associated with this new capability.

FINANCIAL & CORPORATE MATTERS

Artrya included in the S&P/ASX All Ordinaries Index

During the Quarter, Artrya was included in the S&P/ASX All Ordinaries Index (ASX: XAO) effective 23 March 2026, following the quarterly rebalancing of the index. The S&P/ASX All Ordinaries Index is designed to measure the 500 largest companies in the Australian equities market, drawn from eligible ASX listed companies. The one-year total return of the Index was 11.29% as of 31 March 2026 and inclusion in this Index should provide greater visibility and benchmarking for investors as Artrya advances its AI-driven medical imaging platform.

Investor engagement

In line with the expansion of domestic and international shareholders, investor engagement activities were active again this Quarter, with management presenting at the Bell Potter Healthcare Conference, the Barrenjoey Healthcare Conference, and the ASX Small-Mid Cap Conference held in Sydney and virtually. These activities were combined with non-deal roadshows in Australia and the United States, along with a number of media and investor interviews including Proactive Investors and Bell Financial Group. As Artrya expands its commercial activities there is a programme of growing investor, broker, and research related activities.

Operating Cashflows for the Quarter & Cash position

During the Quarter, the Company's cashflows from operating activities included:

- **Customer receipts** of $0.05M related to the receipt of subscription and fee-per-scan plaque revenue. At this early commercial launch phase, timing differences have contributed to a variance in customer receipts from the previous quarters. Invoicing for fee-per-scan revenues is also performed in arrears and was not received during this Quarter.
- **Operating costs (excluding interest income and R&D rebate)** of $6.8M, up from $5.4M in the prior quarter, primarily due to an increase in research & development costs, relating to the ongoing work on the FDA submission for Salix® Coronary Flow and staff costs to support US expansion and onboarding of the new U.S. customers.
- **R&D tax rebate** of $5.6M for the financial year ended 30 June 2025, net of income tax payable. The cash rebate from AusIndustry and the Australian Tax Office relates to eligible R&D expenditure during the 2025 financial year.
- **Interest income** of $0.5M, earned on term deposits.
- **Related party payments** of $0.2M for fees and salaries paid to Directors and their related entities.

Financing Cashflows for the Quarter were $0.75M from the exercise of options and total Net Cash Inflows for this Quarter were $0.06M.

Additionally, Artrya continues to hold a $30.0M six-month, bank term deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of the Appendix 4C and is excluded from cash and cash equivalents. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.

At 31 March 2026, the Company held $76.6M of cash and term deposits.

Quarterly Investor Webinar

The Company's Co-Founder and CEO, John Konstantopoulos, will host a Quarterly Investor Webinar at 12:30pm AEST (10:30am AWST) on 1 May 2026 to discuss the Company's activities, results and outlook.

Senior executives from Tanner Health, who are currently in Australia, will join the webinar in person to provide an update on the progress and clinical adoption of the Salix® platform across the Tanner Health hospital system.

A recording of the webinar will be available on the Investor Centre section of the Company's website for 60 days after the call. Shareholders will also have an opportunity to participate in a Q&A session at the end of the briefing.

Date: **1 May 2026**

Time: **10:30am AWST / 12:30pm AEST**

To pre-register for this conference, please use the following link below:

https://artrya.zoom.us/webinar/register/WN_7qmwbBYNQjSApKkxvwqToQ

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

For more information:

Corporate Enquiries

John Konstantopoulos
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
Artrya Limited	
ABN	**Quarter ended ("current quarter")**
53 624 005 741	31 March 2026

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (9 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	46	116
1.2	Payments for		
	research and development	(1,592)	(2,594)
	product manufacturing and operating costs	(1,448)	(4,655)
	advertising and marketing	(149)	(492)
	leased assets	(88)	(281)
	staff costs	(2,735)	(7,329)
	administration and corporate costs	(797)	(2,102)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	529	1,015
1.5	Interest and other costs of finance paid	(4)	(14)
1.6	Income taxes paid	-	(5)
1.7	Government grants and tax incentives	5,566	5,566
1.8	Other (provide details if material)	-	(835)
1.9	**Net cash from / (used in) operating activities**	**(672)**	**(11,610)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	businesses	-	-
	property, plant and equipment	(3)	(86)
	investments (term deposit)	-	(30,000)
	intellectual property	-	-
	other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
2.2	Proceeds from disposal of:		
	(b) entities	-	-
	businesses	-	-
	property, plant and equipment	-	-
	investments	-	-
	intellectual property	-	-
	other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**(3)**	**(30,086)**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	80,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	750	1,845
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(4,871)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other	-	-
3.10	**Net cash from / (used in) financing activities**	**750**	**76,974**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	46,521	11,332
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(672)	(11,610)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(3)	(30,086)

Consolidated statement of cash flows		Current quarter $A'000	Year to date (9 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	750	76,974
4.5	Effect of movement in exchange rates on cash held	(12)	(26)
4.6	**Cash and cash equivalents at end of period**	**46,584**	**46,584**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	46,584	46,521
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above) ***	**46,584**	**46,521**

* ***The Company has invested $30 million of its cash reserves into a short-term, six-month bank deposit as part of treasury management activities. This term deposit is classified as a financial asset under AASB 9 and is not considered cash or cash equivalents for the purposes of this Appendix 4C. Accordingly, the investment is excluded from cash and cash equivalents at quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.***

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	200
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (see table 7.6 below)	-	-
7.4	**Total financing facilities**	-	-
7.5	**Unused financing facilities available at quarter end**		-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

n/a

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(672)
8.2	Cash and cash equivalents at quarter end (item 4.6)	46,584
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	46,584
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)** **Note: The Company has available investment funds held in a short-term, six-month bank term deposit of $30 million that is excluded from cash and cash equivalents at the quarter end. The investment is readily realisable but does not meet the definition of cash equivalents due to its original maturity exceeding three months.**	69

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: N/A

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: N/A

8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?
Answer: N/A	

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: **30 April 2026**

Authorised by: **Board of Directors, Artrya Limited**

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.